Goldman Sachs raised the firm’s price target on Teradyne (TER) to $300 from $230 and keeps a Buy rating on the shares. The firm expects the stock to hold significant gains following a very strong quarter and guidance that should be sustainable in the medium term despite the bullish expectations, the analyst tells investors in a research note. The firm adds it was encouraged by the management’s revised target model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TER:
- Teradyne: AI-Driven Test Demand and Expanding ATE Market Support Multi-Year Growth and Buy Rating
- Teradyne price target raised to $288 from $229 at Morgan Stanley
- Early notable gainers among liquid option names on February 3rd
- Teradyne sees 60% of sales in 2H26, 40% in 1H
- Teradyne says expects to achieve GPU test qualification